Compare SBCF & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBCF | CPRX |
|---|---|---|
| Founded | 1926 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.4B |
| IPO Year | 2009 | 2006 |
| Metric | SBCF | CPRX |
|---|---|---|
| Price | $30.53 | $31.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $38.00 | $35.00 |
| AVG Volume (30 Days) | 810.8K | ★ 3.2M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | 10.56 | ★ 28.24 |
| EPS | 0.29 | ★ 0.50 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | $45.04 | $9.20 |
| Revenue Next Year | $6.30 | $10.51 |
| P/E Ratio | $105.09 | ★ $62.57 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $24.46 | $19.05 |
| 52 Week High | $35.55 | $32.56 |
| Indicator | SBCF | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 72.98 |
| Support Level | $29.26 | $22.24 |
| Resistance Level | $32.23 | $31.29 |
| Average True Range (ATR) | 0.72 | 0.31 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 43.58 | 95.59 |
Seacoast Banking Corp of Florida is a holding company. The company provides integrated financial services, including commercial and consumer banking, wealth management, and mortgage and insurance services, to customers across Florida through branch, mobile, and online banking solutions. It maintains day-to-day operations, particularly in the areas of operations, treasury management systems, information technology, and security. The company has one reportable segment that provides these integrated financial services, with segment revenues driven mainly by interest and fees on loans, interest on cash and cash equivalents, and investment securities, and fees on depository products and services.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.